This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related letter  • Related article  • Similar articles in this journal  Topic Collections  • Epilepsy  • Neurology, Other  • Oncology  • Brain Cancer  • Alert me on articles by topic  Social Bookmarking   What's this?

Svetlana Blitshteyn, MD; Kurt A. Jaeckle, MD

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

We read with interest the study by Cavaliere et al.¹ We are particularly intrigued by their report of a 30-day mortality rate of 50% in patients with systemic cancer and brain metastases presenting in convulsive status epilepticus (CSE). We have recently reported a series of 4 patients with systemic cancer presenting in de novo nonconvulsive status epilepticus (NCSE) who were diagnosed with metastatic CNS disease via brain imaging at the time of presentation.² All patients demonstrated improvement in mental status after treatment with anticonvulsants; however, 2 patients died at 5 and 20 days, respectively, after the onset of NCSE. Although the number of patients in our series was small, the 30-day mortality of 50% in patients with NCSE is the same as in the series by Cavaliere et al of 10 patients with systemic cancer and CSE.

Nonconvulsive status epilepticus is a more . . . [Full Text of this Article]

AUTHOR INFORMATION



CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTER

Status Epilepticus in Patients With CNS Metastases—Reply
David Schiff and Robert Cavaliere
Arch Neurol. 2007;64(6):916-917.
EXTRACT | FULL TEXT  

RELATED ARTICLE

Clinical Implications of Status Epilepticus in Patients With Neoplasms
Robert Cavaliere, Elana Farace, and David Schiff
Arch Neurol. 2006;63(12):1746-1749.
ABSTRACT | FULL TEXT